Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS

KRAS mutations in non-small-cell lung cancer (NSCLC) patients are considered a negative predictive factor and indicate poor response to anticancer treatments. KRAS mutations lead to activation of the PI3K/akt/mTOR pathway, whose inhibition remains a challenging clinical target. Since the PI3K/akt/mT...

Descripción completa

Detalles Bibliográficos
Autores principales: Caiola, Elisa, Brunelli, Laura, Marabese, Mirko, Broggini, Massimo, Lupi, Monica, Pastorelli, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239488/
https://www.ncbi.nlm.nih.gov/pubmed/27283493
http://dx.doi.org/10.18632/oncotarget.9849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239488/
https://www.ncbi.nlm.nih.gov/pubmed/27283493
http://dx.doi.org/10.18632/oncotarget.9849

Ejemplares similares